Ultragenyx Pharma (RARE) Misses Q2 EPS by 51c; Reaffirms Product Revenue Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts RARE Hot Sheet
Join SI Premium – FREE
Ultragenyx Pharma (NASDAQ: RARE) reported Q2 EPS of ($2.26), $0.51 worse than the analyst estimate of ($1.75). Revenue for the quarter came in at $89.3 million versus the consensus estimate of $87.65 million.
GUIDANCE:
Reaffirm 2022 Crysvita revenue in Ultragenyx territories guidance of $250 million to $260 million and Dojolvi revenue of $55 million to $65 million
For earnings history and earnings-related data on Ultragenyx Pharma (RARE) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman Sachs Downgrades Norsk Hydro SA (NHY:NO) (NHYDY) to Neutral
- First Hawaiian (FHB) Misses Q3 EPS by 7c
- Goldman Sachs sees US stocks dip on tech earnings and macro shifts
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
